Preferred Label : dextroamphetamine;

MeSH definition : The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.;

MeSH synonym : dexamfetamine; d amphetamine; d-amphetamine; dexamphetamine; dextro amphetamine; dextro-amphetamine;

CISMeF synonym : GlaxoSmithKline brand of dextroamphetamine sulfate; celltech brand of dextroamphetamine sulfate; mallinckrodt brand of dextroamphetamine sulfate; pasadena brand of dextroamphetamine; shire brand of dextroamphetamine sulfate; vortech brand of dextroamphetamine sulfate;

MeSH hyponym : oxydess; DextroStat; dextroamphetamine sulfate; curban; dexedrine; Sulfate, Dextroamphetamine; Dextro-Amphetamine Sulfate; Dextro Amphetamine Sulfate; d-Amphetamine Sulfate; d Amphetamine Sulfate;

MeSH CAS label : benzeneethanamine, alpha-methyl-, (S)-;

MeSH Related Number : 51-64-9 (Dextroamphetamine); dextroamphetamine sulfate; JJ768O327N;

Registry Number MeSH : 51-64-9;

Related CAS MeSH : JJ768O327N (Dextroamphetamine sulfate);

Wikipedia link : https://en.wikipedia.org/wiki/Dextroamphetamine;

Codes EINECS : 200-112-1;

Is substance : O;

UNII : TZ47U051FI;

InChIKey : KWTSXDURSIMDCE-QMMMGPOBSA-N;

Details


Main resources

You can consult :

The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.

https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/portraits-decrivant-les-interventions-pharmacologiques-et-non-pharmacologiques-entourant-le-trouble-du-deficit-de-lattention-avec-ou-sans-hyperactivite-tdah-chez-les-quebecois-de-25-ans-et-moins.html
2017
false
false
false
Canada
French
practice guideline
attention deficit disorder with hyperactivity
child
adolescent
young adult
quebec
review of literature
central nervous system stimulants
methylphenidate
dextroamphetamine
Delayed-Action preparations
Lisdexamfetamine Dimesylate
Atomoxetine Hydrochloride
centrally acting sympathomimetics
age factors
sex factors
drug utilization
drug utilization

---
http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/03vol29/acs-dcc-11/index_f.html
http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/03vol29/acs-dcc-11/index.html
2003
Canada
French
English
travel medicine
motion sickness
motion sickness
signs and symptoms
risk factors
motion sickness
incidence
motion sickness
diagnosis, differential
motion sickness
motion sickness
dextroamphetamine
dextroamphetamine
adrenergic uptake inhibitors
adrenergic uptake inhibitors
cinnarizine
cinnarizine
cyclizine
dimenhydrinate
dimenhydrinate
meclizine
promethazine
promethazine
Scopolamine
canada
united states
travel
cyclizine
dimenhydrinate
meclizine
Scopolamine
adrenergic uptake inhibitors
antiemetics
antiemetics
cyclizine
meclizine
Scopolamine
cinnarizine
promethazine
antiemetics
Evidence-Based medicine
journal article
guidelines

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.